Author

Alessandro Ghiringhelli

Institute of Oncology Research

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Alberto Jesus. ArribasiD· 2 shared Andrea RinaldiiD· 2 shared Francesco BertoniiD· 2 shared Giulio SartoriiD· 2 shared Luciano CascioneiD· 2 shared Alex ZadroiD· 1 shared Chiara Falzarano· 1 shared David W. ScottiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alberto Jesus. ArribasORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The RNA helicase DDX21 cooperates with ETS1 and FLI1 in cell cycle, immune evasion, and snoRNA processing in activated B-cell-like diffuse large B-cell lymphoma cells

Giulio Sartori, Valdemar Priebe, Luciano Cascione, Mélanie Juilland, Vincenza Guzzardo, Marco Pizzi, Elaine YL Chung, Sara Napoli, Alberto J. Arribas, Alessandro Ghiringhelli, Stefano Giuffrida, Mattia Forcato, Andrea Rinaldi, Paola Barraja, Silvio Bicciato, , Francesco Bertoni

This study identifies DDX21 as a key effector of ETS1/FLI1 in ABC-DLBCL, linking it to cell cycle, immune evasion, and snoRNA processing, with potential therapeutic implications.

bioRxiv · Jun 5, 2026 · PreprintCancer Biology

Targeting Aberrant FGFR Signaling with Infigratinib Enhances the Efficacy of BTK/PI3K Inhibitors and Bendamustine in Lymphoma Cells

Giulio Sartori, Alessandro Ghiringhelli, Eleonora Cannas, Francesca Guidetti, Alberto Jesus. Arribas, Alex Zadro, Luciano Cascione, Chiara Falzarano, Martina Imbimbo, Matteo Moretti, Andrea Rinaldi, Emanuela Lovati, Francesco Bertoni

This study shows that combining infigratinib with BTK/PI3K inhibitors or bendamustine improves efficacy in lymphoma cell models, reversing resistance and suggesting FGFR inhibition as a therapeutic strategy.

bioRxiv · Dec 25, 2025 · PreprintCancer Biology